



# Thromboses and Hemostasis Disorders Associated with Coronavirus Disease 2019: The Possible Causal Role of Cross-Reactivity and Immunological Imprinting

Darja Kanduc<sup>1</sup>

<sup>1</sup> Department of Biosciences, Biotechnologies and Biopharmaceutics, University of Bari, Bari, Italy

Global Med Genet

**Address for correspondence** Darja Kanduc, PhD, Department of Biosciences, Biotechnologies, and Biopharmaceutics, University of Bari, Via Orabona 4, Bari 70125, Italy (e-mail: dkanduc@gmail.com).

## Abstract

By examining the issue of the thromboses and hemostasis disorders associated with severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) through the lens of cross-reactivity, it was found that 60 pentapeptides are shared by SARS-CoV-2 spike glycoprotein (gp) and human proteins that— when altered, mutated, deficient or, however, improperly functioning— cause vascular diseases, thromboembolic complications, venous thrombosis, thrombocytopenia, coagulopathies, and bleeding, inter alia. The peptide commonality has a relevant immunological potential as almost all of the shared sequences are present in experimentally validated SARS-CoV-2 spike gp-derived epitopes, thus supporting the possibility of cross-reactions between the viral gp and the thromboses-related human proteins. Moreover, many of the shared peptide sequences are also present in pathogens to which individuals have previously been exposed following natural infection or vaccinal routes, and of which the immune system has stored imprint. Such an immunological memory might rapidly trigger anamnestic secondary cross-reactive responses of extreme affinity and avidity, in this way explaining the thromboembolic adverse events that can associate with SARS-CoV-2 infection or active immunization.

## Keywords

- ▶ COVID-19
- ▶ SARS-CoV-2 spike gp
- ▶ cross-reactivity
- ▶ immunological imprinting
- ▶ thromboses-related proteins
- ▶ thromboses
- ▶ vascular diseases
- ▶ bleeding

## Introduction

Clinical studies have shown that severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection can lead to an increased incidence of disorders such as thrombosis, venous thrombosis, and pulmonary embolism.<sup>1–3</sup> A main conclusion of these studies is that, although it cannot be proven that the hypercoagulable state is a direct causative effect of SARS-CoV-2 infection, nonetheless it is apparent that patients with SARS-CoV-2 could have a predilection to the occurrence of thromboembolic events.<sup>1</sup>

However, currently there are no hypotheses or data that might suggest a molecular mechanism that relates to such SARS-CoV-2-related thromboembolic events. Searching for possible mechanisms, the present study analyzes the SARS-CoV-2 spike glycoprotein (gp) for peptide sharing, that is, molecular mimicry, with human proteins, alterations of which may cause thromboses and hemostasis diseases. The underlying scientific rationale is that peptides common to a pathogen and the human host may lead to autoimmune pathologies through cross-reactivity phenomena following pathogen infection.<sup>4–6</sup> The results indicate that several linear

DOI <https://doi.org/10.1055/s-0041-1731068>.  
ISSN 2699-9404.

© 2021. The Author(s).

This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (<https://creativecommons.org/licenses/by/4.0/>)  
Georg Thieme Verlag KG, Rüdigerstraße 14, 70469 Stuttgart, Germany

sequences shared between the SARS-CoV-2 spike gp and human proteins related to thromboembolic events can possibly generate pathogenic autoantibodies via cross-reactivity and immunologic imprinting phenomena, in this way leading to thromboses and hemostasis disorders.

### Materials and Methods

Peptide sharing between spike gp (NCBI, GenBank Protein Accession, ID: QHD43416.1) from SARS-CoV-2 and human proteins related to thromboses and hemostasis disorders was analyzed as previously detailed.<sup>4-6</sup> In brief, pentapeptides were used as sequence probes since a peptide grouping formed by five amino acid (aa) residues defines a minimal immune determinant that can (1) induce highly specific antibodies, and (2) determine antigen-antibody specific interaction.<sup>7,8</sup> Human proteins linked to thromboses and hemostasis disorders were retrieved from UniProtKB database ([www.uniprot.org](http://www.uniprot.org)).<sup>9</sup> Methodologically the spike gp primary sequence was dissected into pentapeptides offset by one residue (i.e., MFVFL, FVFLV, VFLVL, FLVLL, and so forth)

and the resulting viral pentapeptides were analyzed for occurrences within the human proteins related to thromboses and hemostasis disorders. Then, the shared peptides were also controlled for occurrences in the pathogens *Bordetella pertussis*, *Corynebacterium diphtheriae*, *Clostridium tetani*, *Haemophilus influenzae*, and *Neisseria meningitidis*.

The immunological potential of the peptides shared between SARS-CoV-2 spike gp and thrombosis-related proteins was analyzed by searching the Immune Epitope DataBase (IEDB [[www.iedb.org/](http://www.iedb.org/)])<sup>10</sup> for immunoreactive SARS-CoV-2 spike gp-derived epitopes hosting the shared pentapeptides.

### Results and Discussion

#### Peptide Sharing between SARS-CoV-2 Spike Glycoprotein and Thromboses-Related Human Proteins

Table 1 shows that 60 minimal immune determinants are shared between SARS-CoV-2 spike gp and 44 human proteins that—when altered, mutated, deficient or, however, improperly functioning—may cause diseases that include

**Table 1** Pentapeptide sharing between SARS-CoV-2 spike gp and human proteins linked when altered, mutated, or deficient to blood diseases

Shared peptides	Human proteins and associated functions/pathologies <sup>a,b</sup>	References
MTKTS, NLLLQ	<i>ADTRP</i> (androgen-dependent TFPI-regulating protein) Regulates the anticoagulant activity of the tissue factor pathway inhibitor, dysfunctions of which lead to vascular diseases	11
TQLPP, PRTFL	<i>ALG12: Dol-P-Man: Man(7)GlcNAc(2)-PP-Dol α-1,6-mannosyltransferase</i> Psychomotor retardation, hypotonia, coagulation disorders, and immunodeficiency	12
SAIGK	<i>ALG8: Dolichyl pyrophosphate Glc1Man9GlcNAc2 α-1,3-glucosyltransferase</i> Pathologies: see ALG12 above	13
AEIRA	<i>ANXA6</i> (annexin A6) Anticoagulant protein from human placenta	14
QLIRA, IRASA	<i>AP3B1</i> (AP-3 complex subunit β-1) Associates with Hermansky-Pudlak syndrome. Bleeding diathesis resulting in bruising, epistaxis, gingival bleeding, postpartum hemorrhage, bleeding	15
LIGAE	<i>APLP2</i> (amyloid-like protein 2) The soluble form may have inhibitory properties toward coagulation factors and regulates cerebral thrombosis	16
VLLPL	<i>B3AT</i> (band 3 anion transport protein) Involved in venous thrombosis of unknown origin	17
FGGVS	<i>B4GT1</i> (β-1,4-galactosyltransferase 1) Defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders	18
KGYHL	<i>C4BPB</i> (C4b-binding protein β chain) Controls complement activation; binds as a cofactor to C3b/C4b inactivator; possibly involved in the susceptibility to venous thrombosis	19,20
LTVLP	<i>CBS</i> (cystathionine β-synthase) CBS-deficient patients are prone to vascular thrombosis	21
NSVAY	<i>CO1A1</i> (collagen α-1(I) chain) Connective tissue disorders characterized by fragile, bruisable skin	22,23
PGQTG, NGLTG	<i>CO1A2</i> (collagen α-2(I) chain) Pathology: see CO1A1 above	22,23
TQSLI, GTGVL	<i>COG1</i> (conserved oligomeric Golgi's complex subunit 1) Psychomotor retardation, hypotonia, coagulation disorders, and immunodeficiency	24

**Table 1** (Continued)

Shared peptides	Human proteins and associated functions/pathologies <sup>a,b</sup>	References
STNLV, GAISS	<i>COG2</i> . (conserved oligomeric Golgi's complex subunit 2) Pathology: as for COG1	25
PINLV	<i>COG5</i> (conserved oligomeric Golgi's complex subunit 5) Pathology: as for COG1	26
LPFQQ, PFQQF, IGKIQ	<i>ENTP1</i> (ectonucleoside triphosphate diphosphohydrolase 1) Implicated in the prevention of platelet aggregation	27,28
YTSAL	<i>EPHB2</i> (ephrin type-B receptor 2) Regulation of platelet activation and blood coagulation	29
VLNDI	<i>F13A</i> (coagulation factor XIII A chain) Relates to hematologic disorders characterized by bleeding tendency	30
DPLQP	<i>FA5</i> (coagulation factor V) Central regulator of hemostasis. Parahemophilia, i.e., poor clotting; pregnancy loss, ischemic stroke, thrombophilia	31–34
PPLLT, FVTQR	<i>FA8</i> (coagulation factor VIII) Hemophilia	35
NSYEC	<i>FA9</i> (coagulation factor IX) Hemophilia	35
SSANN	<i>FIBA</i> (fibrinogen $\alpha$ chain) Bleeding, amyloidosis, arterial hypertension, hepatosplenomegaly, cholestasis, petechial skin rash; thromboembolic complications	36–38
GAGAA	<i>GATA4</i> (transcription factor GATA-4) Regulates factor X, a vitamin K-dependent serine protease that functions in blood coagulation. Can predispose to dilated cardiomyopathy, and to premature death	39–41
NDPFL	<i>GP1BA</i> (platelet glycoprotein Ib $\alpha$ chain) Epistaxis; hemorrhage; menorrhagia; purpura; congenital bleeding diathesis; large platelets; thrombocytopenia; long bleeding time	42
ALLAG	<i>GPIX</i> (platelet glycoprotein IX) Epistaxis; hemorrhage; menorrhagia; purpura; congenital bleeding diathesis; large platelets; thrombocytopenia; long bleeding time	42
KLIAN	<i>HABP2</i> (hyaluronan-binding protein 2) Serine protease involved in coagulation fibrinolysis and inflammatory pathways	43
TQLPP	<i>HPS4</i> (Hermansky–Pudlak syndrome 4 protein) Epistaxis; reduced visual acuity; horizontal nystagmus; iris transillumination; restrictive lung disease; bruising; bleeding tendency; menorrhagia; absence of platelet dense bodies; lack of secondary aggregation response of platelets	44
HTSPD	<i>HPS5</i> (Hermansky–Pudlak syndrome 5 protein) As HPS4 above	45
FNATR, DRLIT	<i>HS3S5</i> (heparan sulfate glucosamine 3-O-sulfotransferase 5) Catalyzes a crucial step in the biosynthesis of the anticoagulant heparan sulfate	46
SASFS	<i>ITA2</i> (integrin $\alpha$ -2) Associates with increased ischemic stroke risk; thrombophilia	47,48
VRDLP	<i>ITB3</i> (integrin $\beta$ -3) Thrombasthenia, characterized by mucocutaneous bleeding	49
FGTTL, YDPLQ, GDISG	<i>JAK2</i> (tyrosine-protein kinase JAK2) Thrombophilia, thrombocytosis	50,51
VNLTT, GDSSS, VTYVP	<i>MMRN1</i> (multimerin-1) Deficiency in multimerin-1 associates with bleeding disorder	52
LLPLV	<i>PLF4</i> (Platelet factor 4) Involved in thrombosis	53
TFGAG	<i>PLMN</i> (plasminogen) may be associated with susceptibility to thrombosis	54
TVEKG, TGTV	<i>PROS</i> : vitamin K-dependent protein S Anticoagulant plasma protein. Helps to prevent coagulation and stimulates fibrinolysis. Deficiency leads to impaired blood coagulation and a tendency to venous thrombosis	55,56

(Continued)

**Table 1** (Continued)

Shared peptides	Human proteins and associated functions/pathologies <sup>a,b</sup>	References
LALHR	<i>PROZ: vitamin K-dependent protein Z</i> Helps hemostasis by binding thrombin and promoting its association with phospholipid vesicles. Deficiency may be a risk factor for retinal vessel occlusion	57
IDRLI	<i>PTPRJ: receptor-type tyrosine-protein phosphatase η</i> Lack of PTPRJ leads to a bleeding tendency and defective arterial thrombosis	58
VFAQV	<i>TF (tissue factor)</i> Initiates blood coagulation by forming a complex with circulating factor VII or VIIa	59
LFKRS	<i>THRB: Prothrombin</i> Functions in blood homeostasis.	60
AGAAL, GAALQ	<i>TRBM (thrombomodulin)</i> Relates to thrombophilia, venous thrombosis, and thromboembolic disease. TRBM administration is beneficial in sepsis-induced coagulopathy and in disseminated intravascular coagulations	61–63
TLLAL	<i>TSP1 (thrombospondin-1)</i> Coronary artery disease	52,64
TLLAL, SCGSC	<i>TSP2 (thrombospondin-2)</i> Coronary artery disease	52,64
VSSQC, LQYGS	<i>VWF (von Willebrand factor)</i> Von Willebrand's disease is characterized by deficiency of circulating VWF that is otherwise structurally and functionally normal. Clinical features: impaired platelet aggregation, cardiovascular diseases, mucocutaneous bleeding, epistaxis, menorrhagia	52,65–67

Abbreviations: gp, glycoprotein; SARS-CoV-2, severe acute respiratory syndrome-coronavirus-2.

<sup>a</sup>Human proteins given by Uniprot accession and name in italics.

<sup>b</sup>Functions and/or pathologies: data and further references from Uniprot, PubMed, and OMIM databases

coagulation disorders, bruising, bleeding, hemorrhages, retinal vessel occlusion, cerebral thrombosis, venous thrombosis, ischemic stroke, and thrombophilia, inter alia.

### Immunological Potential of the Viral versus Human Peptide Sharing

The data shown in ► **Table 1** are quantitatively impressive and become strikingly preeminent from a pathological perspective when analyzed for their immunological potential. Indeed, exploration of the IEDB<sup>10</sup> reveals that nearly all the shared pentapeptides described in ► **Table 1** are also disseminated among SARS-CoV-2 spike gp-derived epitopes that have been experimentally validated as immunoreactive and are cataloged at the IEDB database (<http://www.iedb.org>).<sup>10</sup>

That is, ► **Table 2** concretely supports the possibility that autoimmune cross-reactions may be triggered by SARS-CoV-2 infection/active immunization and hit human proteins related to thrombotic/thromboembolic disorders and coagulopathies, inter alia. Clinically, the vastity of the potential immunological cross-reactivity that emerges from ► **Table 2** indicates that mild-to-moderate and severe forms of thrombosis and coagulopathy may unavoidably accompany SARS-CoV-2 infection/active immunization.

### Autoimmunity Potential and the Immunological Memory

As already highlighted also in other infection models,<sup>68–71</sup> one has to consider that immunologic memory can

powerfully enhance and amplify the autoimmune cross-reactivity potential because of interpathogen peptide sharing. Indeed, as a rule, the immune system recalls preexisting memory responses toward past infections rather than inducing ex novo responses toward the recent ones since hallmark of the immune system is the memory for the immune determinants it has previously encountered.<sup>72,73</sup>

Here, comparative sequence analyses show that 31 out of the 60 minimal immune determinants common to SARS-CoV-2 spike gp and human proteins related to thromboses are also widespread in pathogens, such as *B. pertussis*, *C. diphtheriae*, *C. tetani*, *H. influenzae*, and *N. meningitidis*, that are in pathogens with which, in general, an individual has already come into contact during his life due to infections or by vaccination (► **Table 3**).

Hence, ► **Table 3** indicates the possibility that a preexisting immune response to previously encountered pathogens (in the present case: *B. pertussis*, *C. tetani*, *C. diphtheriae*, *H. influenzae*, and/or *N. meningitidis*) might be magnified and intensified following SARS-CoV-2 infection/active immunization. That is, immunological imprinting can start a chain of events according to which followings can be measured:

- Following exposure to SARS-CoV-2, the primary response to the virus can turn into a secondary response to previously encountered pathogens of which the immune system has stored an immunological memory.
- The anamnestic secondary and, by definition, extremely powerful response against immune determinants

**Table 2** Distribution of peptides shared between SARS-CoV-2 spike gp and human proteins related to thromboses and hemostasis disorders among 94 experimentally validated SARS-CoV-2 spike gp-derived epitopes

ID <sup>a</sup>	Epitope <sup>b</sup>	ID <sup>a</sup>	Epitope <sup>b</sup>
1069137	aqYTSALLAGtitsg	1309555	qcVNLTTrTQLPPaytnsft
1069290	ctlksfTVEKGiyqt	1309558	qfnSAIGKIQdlsstasal
1071585	nLVRDLPqgfsalep	1309564	qtragcLIGAEhvnNSYECd
1071723	patvcgpkkSTNLVknkc	1309573	rLFRKSnlkipferdistei
1072807	skhtPINLVRDLPqg	1309595	tnftisvtteilpvsMTKTS
1072965	svtteilpvsMTKTS	1309598	tvYDPLQPeldsfkeeldky
1073281	tesnkkfLPFQQFgrdia	1309599	TyypaqeknfTtapaichdg
1073938	vqIDRLITgrlqslq	1309600	tyvtqQLIRAAEIRASAnla
1074201	ylrLFRKSnlkipfe	1309602	vcgpkkSTNLVknkcvnf
1074838	AEIRASAnlaatk	1309603	vknkcvnfNGLTGTGVLt
1074925	hVTYVPaqeknf	1309604	VLNDIlrldkveaevqidr
1074969	lgaenSVAYsnn	1309621	yskhtPINLVRDLPqgfsal
1074974	ILALHRsyl	1310254	aeNSVAYsnnsiaip
1075005	nqKLIANqf	1310281	aphgvflhVTYVPa
1075031	rLFRKSnlk	1310303	caqkfngLTVLPpll
1075039	rqiaPGQTGkiadynykl	1310336	dskTQSLlivnatn
1075066	sVLNDIlrld	1310392	FGTTLdskTQSLliv
1075079	tPINLVRdl	1310401	fkiyskhtPINLVRd
1075085	tvYDPLQPeldsfk	1310415	fngLTVLPPLLTdem
1075094	viPPLLTdemiaqyt	1310434	GAISSVLNDIlrld
1075125	ysvlynSASFStfk	1310444	givntvYDPLQPel
1075131	yyvgylqPRTFLI	1310487	iginitrfqTLLALh
1087680	PINLVRDLPqgfsalepl	1310506	irgwiFGTTLdsktq
1125063	gLTVLPpll	1310513	itrqTLLALHRsyl
1309117	ggnylyrLFRKSn	1310592	ILALHRsyltpgdss
1309118	gpkkSTNLVknkcvn	1310611	IPPLLTdemiaqyts
1309123	khtPINLVRDLPqgf	1310633	lyenqKLIANqfnsa
1309140	tdemiaqYTSALLAG	1310787	SASFStfkcygvspt
1309147	ylqPRTFLI	1310828	svlynSASFStfkcy
1309418	AEIRASAnlaatkmscvlg	1310852	tlvkqlssnfGAISS
1309442	ayyvgylqPRTFLIkyneng	1310865	trfqTLLALHRsylt
1309450	dplsetkctlksfTVEKGiy	1310899	VLLPLVSSQCVNLTT
1309451	dsfkeeldkyfknHTSPDvd	1310909	VNLTTrTQLPPaytn
1309461	ehvnNSYECdipigagicas	1310927	vtqnvlyenqKLIAN
1309464	esnkkfLPFQQFgrdiadt	1310947	wTFGAGAALQipfam
1309469	fknHTSPDvdlGDISGinas	1310979	yvgylqPRTFLIkyn
1309470	fknidgyfkiyskhtPINLV	1311657	ccSCGSCckfddedsepvlkgvkl
1309475	gccSCGSCckfddedsepvl	1311813	rLFRKSnlkip
1309492	ilditpcsFGGVsvitpgtn	1313244	nSASFStfk
1309506	kvggnylyrLFRKSnlkip	1313285	PINLVRDLPqgfsal
1309515	lhryltpGDSSSgwtagaa	1313286	PINLVRDLPqgfwal
1309516	litgrlqslqtyvtqQLIRA	1314023	ynylyrLFRKSnlkip
1309523	lssnfGAISSVLNDIlrld	1317916	gylqPRTFLI

(Continued)

**Table 2** (Continued)

ID <sup>a</sup>	Epitope <sup>b</sup>	ID <sup>a</sup>	Epitope <sup>b</sup>
1309524	lyenqKLIANqfnSAIGKIQ	1321084	IPPLLTdem
1309531	NGLTGTGVLtesnkkflpfq	1327418	vYDPLQPeldsf
1309532	ngLTVLPPLLTemiaqyts	1327923	yenqKLIANqf
1309534	nitrfaqTLLALHRSyltpgd	1328800	ytmslgaeNSVAY

Abbreviations: gp, glycoprotein; SARS-CoV-2, severe acute respiratory syndrome-coronavirus-2.

<sup>a</sup>Epitopes listed as the Immune Epitope DataBase ID.

<sup>b</sup>Shared peptides given in capital letters.

**Table 3** Occurrence in microbial organisms of pentapeptides common to SARS-CoV-2 spike gp, SARS-CoV-2 spike gp-derived epitome, and human proteins related to thromboses, coagulopathies, and hemostasis disorders

Organism	Shared peptides
<i>Bordetella pertussis</i>	AEIRA, AGAAL, ALLAG, GAALQ, GAGAA, LLPLV, PFQQF, QLIRA, SSANN, TGTGV, VLLPL, YDPLQ
<i>Corynebacterium diphtheriae</i>	AEIRA, AGAAL, ALLAG, DPLQP, GAALQ, GAGAA, GTGVL, LLPLV, TVEKG
<i>Clostridium tetani</i>	AGAAL, LQYGS
<i>Haemophilus influenzae</i>	AEIRA, AGAAL, FGGVS, GAALQ, GAGAA, GTGVL, KLIAN, LALHR, LLPLV, LPFQQ, LTVLP, NLLLQ, NSVAY, TLLAL, TQSLL, VLLPL, VLNDI, VNLTT, YTSAL
<i>Neisseria meningitidis</i>	AEIRA, AGAAL, ALLAG, DRLIT, GAALQ, GAGAA, IDRLI, KLIAN, LALHR, LTVLP, PINLV, TLLAL, VLLPL, VLNDI

Abbreviations: gp, glycoprotein; SARS-CoV-2, severe acute respiratory syndrome-coronavirus-2.

previously encountered implies not only that a low or no immune response will be evoked against the pathogen lastly encountered, that is, SARS-CoV-2, but also entails that the anamnestic secondary reaction against the early sensitizing pathogens—in the case in point, *B. pertussis*, *C. tetani*, *C. diphtheriae*, and/or *N. meningitidis*—will fail because those early sensitizing pathogens are no more present in the organism.

- As a final result, the anamnestic, high affinity, high avidity, and extremely powerful secondary immune response triggered by the lastly encountered pathogen (SARS-CoV-2) and addressed toward past infections may find an outlet by hitting available human targets, that is, in the case in object, the human proteins related to thromboses and hemostasis diseases (►Table 1).

### Conclusion

The last decades have seen the emerging of infectious diseases and, consequently, intensive application of immunization procedures. Concomitantly, concerns about possible adverse events have increased. A recent crucial example is the immunization campaign with the dengue vaccine that highlighted the risk of enhanced disease after vaccination.<sup>74</sup>

Today, the clinical context associated with SARS-CoV-2 infection/active immunization is no different. Actually, understanding whether undesired collateral events, such as the thrombotic manifestations and bleeding disorders discussed in this study, may causally associate with the viral infection/active immunization is a fundamental step for

fighting the current pandemic. In this context, the present study:

- Analyzed the hypothesis that infectious agents can induce cross-reactive autoantibodies capable of hitting and altering human proteins that regulate hemostasis and coagulation.
- Showed that numerous peptides endowed with an immunologic potential are common to SARS-CoV-2 spike gp and human proteins, when mutated, altered, deficient or improperly functioning, are associated with thromboses and hemostasis diseases (►Tables 1 and 2).
- Documented that the peptide commonality extends to pathogens that usually have been already encountered by an individual during his life (►Table 3).

Scientifically, the data indicate that peptide sharing-associated cross-reactivity and, in conjunction, immunological imprint might help explain some of the thromboembolic events that rapidly, massively, and violently may arise following SARS-CoV-2 infection/active immunization.

Clinically, the present data warrant testing of patients' sera for autoantibodies against the peptide targets described in ►Tables 1–2 and 3, and reiterate the suggestion advanced already in 2000<sup>75</sup> that immunotherapies should take advantage of the principle of peptide uniqueness, that is, of peptides present in the antigen of interest and absent in the human proteome.<sup>71,76–81</sup>

### Funding

None.



**Conflict of Interest**

None declared.

**References**

- 1 Ng JJ, Choong AMTL. Thromboembolic events in patients with SARS-CoV-2. *J Vasc Surg* 2020;72(02):760–761
- 2 Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. *J Thromb Haemost* 2020;18(06):1421–1424
- 3 Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. *Thromb Res* 2020;191:145–147
- 4 Lucchese G, Capone G, Kanduc D. Peptide sharing between influenza A H1N1 hemagglutinin and human axon guidance proteins. *Schizophr Bull* 2014;40(02):362–375
- 5 Lucchese G, Kanduc D. Potential crossreactivity of human immune responses against HCMV glycoprotein B. *Curr Drug Discov Technol* 2016;13(01):16–24
- 6 Lucchese G, Kanduc D. Zika virus and autoimmunity: From microcephaly to Guillain-Barré syndrome, and beyond. *Autoimmun Rev* 2016;15(08):801–808
- 7 Kanduc D. Pentapeptides as minimal functional units in cell biology and immunology. *Curr Protein Pept Sci* 2013;14(02):111–120
- 8 Kanduc D. Homology, similarity, and identity in peptide epitope immunodefinition. *J Pept Sci* 2012;18(08):487–494
- 9 UniProt Consortium. UniProt: a worldwide hub of protein knowledge. *Nucleic Acids Res* 2019;47(D1):D506–D515
- 10 Vita R, Mahajan S, Overton JA, et al. The Immune Epitope Database (IEDB): 2018 update. *Nucleic Acids Res* 2019;47(D1):D339–D343
- 11 Lupu C, Zhu H, Popescu NI, Wren JD, Lupu F. Novel protein ADTRP regulates TFPI expression and function in human endothelial cells in normal conditions and in response to androgen. *Blood* 2011;118(16):4463–4471
- 12 Thiel C, Schwarz M, Peng J, et al. A new type of congenital disorders of glycosylation (CDG-II) provides new insights into the early steps of dolichol-linked oligosaccharide biosynthesis. *J Biol Chem* 2003;278(25):22498–22505
- 13 Schollen E, Frank CG, Keldermans L, et al. Clinical and molecular features of three patients with congenital disorders of glycosylation type I<sub>h</sub> (CDG-I<sub>h</sub>) (ALG8 deficiency). *J Med Genet* 2004;41(07):550–556
- 14 Yoshizaki H, Mizoguchi T, Arai K, Shiratsuchi M, Shidara Y, Maki M. Structure and properties of calphobindin II, an anticoagulant protein from human placenta. *J Biochem* 1990;107(01):43–50
- 15 Huizing M, Malicdan MCV, Wang JA, et al. Hermansky-Pudlak syndrome: mutation update. *Hum Mutat* 2020;41(03):543–580
- 16 Xu F, Previti ML, Nieman MT, Davis J, Schmaier AH, Van Nostrand WE. AbetaPP/APLP2 family of Kunitz serine proteinase inhibitors regulate cerebral thrombosis. *J Neurosci* 2009;29(17):5666–5670
- 17 Chang WA, Sheu CC, Liu KT, Shen JH, Yen MC, Kuo PL. Identification of mutations in SLC4A1, GP1BA and HFE in a family with venous thrombosis of unknown cause by next-generation sequencing. *Exp Ther Med* 2018;16(05):4172–4180
- 18 Hansske B, Thiel C, Lübke T, et al. Deficiency of UDP-galactose: N-acetylglucosamine beta-1,4-galactosyltransferase I causes the congenital disorder of glycosylation type II<sub>d</sub>. *J Clin Invest* 2002;109(06):725–733
- 19 Blom AM, Villoutreix BO, Dahlbäck B. Functions of human complement inhibitor C4b-binding protein in relation to its structure. *Arch Immunol Ther Exp (Warsz)* 2004;52(02):83–95
- 20 Buil A, Trégouët DA, Souto JC, et al. C4BPB/C4BPA is a new susceptibility locus for venous thrombosis with unknown protein S-independent mechanism: results from genome-wide association and gene expression analyses followed by case-control studies. *Blood* 2010;115(23):4644–4650
- 21 Sikora M, Lewandowska I, Marczak Ł, Bretes E, Jakubowski H. Cystathionine β-synthase deficiency: different changes in pro-teomes of thrombosis-resistant Cbs<sup>-/-</sup> mice and thrombosis-prone CBS<sup>-/-</sup> humans. *Sci Rep* 2020;10(01):10726
- 22 Nuytinck L, Freund M, Lagae L, Pierard GE, Hermanns-Le T, De Paepe A. Classical Ehlers-Danlos syndrome caused by a mutation in type I collagen. *Am J Hum Genet* 2000;66(04):1398–1402
- 23 Malfait F, Symoens S, De Backer J, et al. Three arginine to cysteine substitutions in the pro-alpha (1)-collagen chain cause Ehlers-Danlos syndrome with a propensity to arterial rupture in early adulthood. *Hum Mutat* 2007;28(04):387–395
- 24 Foulquier F, Vasile E, Schollen E, et al. Conserved oligomeric Golgi complex subunit 1 deficiency reveals a previously uncharacterized congenital disorder of glycosylation type II. *Proc Natl Acad Sci U S A* 2006;103(10):3764–3769
- 25 Kodera H, Ando N, Yuasa I, et al. Mutations in COG2 encoding a subunit of the conserved oligomeric golgi complex cause a congenital disorder of glycosylation. *Clin Genet* 2015;87(05):455–460
- 26 Paesold-Burda P, Maag C, Troxler H, et al. Deficiency in COG5 causes a moderate form of congenital disorders of glycosylation. *Hum Mol Genet* 2009;18(22):4350–4356
- 27 Kaczmarek E, Koziak K, Sévigny J, et al. Identification and characterization of CD39/vascular ATP diphosphohydrolase. *J Biol Chem* 1996;271(51):33116–33122
- 28 Savio LEB, Robson SC, Longhi MS. Ectonucleotidase modulation of lymphocyte function in gut and liver. *Front Cell Dev Biol* 2021;8:621760
- 29 Berrou E, Soukaseum C, Favier R, et al. A mutation of the human *EPHB2* gene leads to a major platelet functional defect. *Blood* 2018;132(19):2067–2077
- 30 Ivaskevicius V, Biswas A, Bevans C, et al. Identification of eight novel coagulation factor XIII subunit A mutations: implied consequences for structure and function. *Haematologica* 2010;95(06):956–962
- 31 Castoldi E, Simioni P, Kalafatis M, et al. Combinations of 4 mutations (FV R506Q, FV H1299R, FV Y1702C, PT 20210G/A) affecting the prothrombinase complex in a thrombophilic family. *Blood* 2000;96(04):1443–1448
- 32 Poursadegh Zonouzi A, Chaparzadeh N, Ghorbian S, et al. The association between thrombophilic gene mutations and recurrent pregnancy loss. *J Assist Reprod Genet* 2013;30(10):1353–1359
- 33 Casas JP, Hingorani AD, Bautista LE, Sharma P. Meta-analysis of genetic studies in ischemic stroke: thirty-two genes involving approximately 18,000 cases and 58,000 controls. *Arch Neurol* 2004;61(11):1652–1661
- 34 Mumford AD, McVey JH, Morse CV, et al. Factor V I359T: a novel mutation associated with thrombosis and resistance to activated protein C. *Br J Haematol* 2003;123(03):496–501
- 35 Al-Allaf FA, Taher MM, Abduljaleel Z, et al. Molecular analysis of factor VIII and factor IX genes in hemophilia patients: identification of novel mutations and molecular dynamics studies. *J Clin Med Res* 2017;9(04):317–331
- 36 Asselta R, Platè M, Robusto M, et al. Clinical and molecular characterisation of 21 patients affected by quantitative fibrinogen deficiency. *Thromb Haemost* 2015;113(03):567–576
- 37 Benson MD, Liepnieks J, Uemichi T, Wheeler G, Correa R. Hereditary renal amyloidosis associated with a mutant fibrinogen alpha-chain. *Nat Genet* 1993;3(03):252–255
- 38 Koopman J, Haverkate F, Grimbergen J, et al. Molecular basis for fibrinogen Dusart (A alpha 554 Arg->Cys) and its association with abnormal fibrin polymerization and thrombophilia. *J Clin Invest* 1993;91(04):1637–1643
- 39 Wilberding JA, Castellino FJ. Characterization of the murine coagulation factor X promoter. *Thromb Haemost* 2000;84(06):1031–1038

- 40 Hung HL, Pollak ES, Kudaravalli RD, Arruda V, Chu K, High KA. Regulation of human coagulation factor X gene expression by GATA-4 and the Sp family of transcription factors. *Blood* 2001;97(04):946–951
- 41 Li RG, Li L, Qiu XB, et al. GATA4 loss-of-function mutation underlies familial dilated cardiomyopathy. *Biochem Biophys Res Commun* 2013;439(04):591–596
- 42 Almomani MH, Mangla A. Bernard soulier syndrome. In: *StatPearls*. Treasure Island, FL: StatPearls Publishing; 2021
- 43 Cheng YC, Stanne TM, Giese AK, et al; WTCCC-2 Consortium. Genome-wide association analysis of young-onset stroke identifies a locus on chromosome 10q25 near HABP2. *Stroke* 2016;47(02):307–316
- 44 Anderson PD, Huizing M, Claassen DA, White J, Gahl WA. Hermansky-Pudlak syndrome type 4 (HPS-4): clinical and molecular characteristics. *Hum Genet* 2003;113(01):10–17
- 45 Botero JP, Chen D, Majerus JA, et al. Hermansky-Pudlak syndrome subtype 5 (HPS-5) novel mutation in a 65 year-old with oculocutaneous hypopigmentation and mild bleeding diathesis: the importance of recognizing a subtle phenotype. *Platelets* 2018;29(01):91–94
- 46 Xia G, Chen J, Tiwari V, et al. Heparan sulfate 3-O-sulfotransferase isoform 5 generates both an antithrombin-binding site and an entry receptor for herpes simplex virus, type 1. *J Biol Chem* 2002;277(40):37912–37919
- 47 Liu H, Wang Y, Zheng J, et al. Platelet glycoprotein gene Ia C807T, HPA-3, and Ibx VNTR polymorphisms are associated with increased ischemic stroke risk: Evidence from a comprehensive meta-analysis. *Int J Stroke* 2017;12(01):46–70
- 48 Reznik EV, Shcherbakova ES, Borisovskaya SV, et al. ST-elevation myocardial infarction, pulmonary embolism, and cerebral ischemic stroke in a patient with critically low levels of natural anticoagulants. *J Cardiol Cases* 2019;21(03):106–109
- 49 French DL, Collier BS. Hematologically important mutations: Glanzmann thrombasthenia. *Blood Cells Mol Dis* 1997;23(01):39–51
- 50 Chung RT, Iafrate AJ, Amrein PC, Sahani DV, Misdraji J. Case records of the Massachusetts General Hospital. Case 15–2006. A 46-year-old woman with sudden onset of abdominal distention. *N Engl J Med* 2006;354(20):2166–2175
- 51 Stockklausner C, Duffert CM, Cario H, Knöfler R, Streif W, Kulozik AETHROMKID-Plus Studiengruppe der Gesellschaft für Thrombose- und Hämostaseforschung (GTH) and of Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH) Thrombocytosis in children and adolescents-classification, diagnostic approach, and clinical management. *Ann Hematol* 2021 (e-pub ahead of print). Doi: 10.1007/s00277-021-04485-0
- 52 Hayward CP, Rivard GE, Kane WH, et al. An autosomal dominant, qualitative platelet disorder associated with multimerin deficiency, abnormalities in platelet factor V, thrombospondin, von Willebrand factor, and fibrinogen and an epinephrine aggregation defect. *Blood* 1996;87(12):4967–4978
- 53 Althaus K, Möller P, Uzun G, et al. Antibody-mediated procoagulant platelets in SARS-CoV-2-vaccination associated immune thrombotic thrombocytopenia. *Haematologica* 2021 May 20. Doi: 10.3324/haematol.2021.279000
- 54 Ichinose A, Espling ES, Takamatsu J, et al. Two types of abnormal genes for plasminogen in families with a predisposition for thrombosis. *Proc Natl Acad Sci U S A* 1991;88(01):115–119
- 55 Boinot C, Borgel D, Kitzis A, Guicheteau M, Aiach M, Alhenc-Gelas M. Familial thrombophilia is an oligogenetic disease: involvement of the prothrombin G20210A, PROC and PROS gene mutations. *Blood Coagul Fibrinolysis* 2003;14(02):191–196
- 56 Makris M, Leach M, Beauchamp NJ, et al. Genetic analysis, phenotypic diagnosis, and risk of venous thrombosis in families with inherited deficiencies of protein S. *Blood* 2000;95(06):1935–1941
- 57 Koren-Michowitz M, Eting E, Rahimi-Levene N, Garach-Jehoshua O, Volcheck Y, Kornberg A. Protein Z levels and central retinal vein or artery occlusion. *Eur J Haematol* 2005;75(05):401–405
- 58 Senis YA, Tomlinson MG, Ellison S, et al. The tyrosine phosphatase CD148 is an essential positive regulator of platelet activation and thrombosis. *Blood* 2009;113(20):4942–4954
- 59 Bogdanov VY, Balasubramanian V, Hathcock J, Vele O, Lieb M, Nemerson Y. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. *Nat Med* 2003;9(04):458–462
- 60 Glenn KC, Frost GH, Bergmann JS, Carney DH. Synthetic peptides bind to high-affinity thrombin receptors and modulate thrombin mitogenesis. *Pept Res* 1988;1(02):65–73
- 61 Ohlin AK, Norlund L, Marlar RA. Thrombomodulin gene variations and thromboembolic disease. *Thromb Haemost* 1997;78(01):396–400
- 62 Vincent JL, Francois B, Zabolotskikh I, et al; SCARLET Trial Group. Effect of a recombinant human soluble thrombomodulin on mortality in patients with sepsis-associated coagulopathy: The SCARLET randomized clinical trial. *JAMA* 2019;321(20):1993–2002
- 63 Vincent JL, Ramesh MK, Ernest D, et al. A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. *Crit Care Med* 2013;41(09):2069–2079
- 64 Zhang XJ, Wei CY, Li WB, et al. Association between single nucleotide polymorphisms in thrombospondins genes and coronary artery disease: A meta-analysis. *Thromb Res* 2015;136(01):45–51
- 65 Allen S, Abuzenadah AM, Hinks J, et al. A novel von Willebrand disease-causing mutation (Arg273Trp) in the von Willebrand factor propeptide that results in defective multimerization and secretion. *Blood* 2000;96(02):560–568
- 66 Horiuchi H, Doman T, Kokame K, Saiki Y, Matsumoto M. Acquired von Willebrand syndrome associated with cardiovascular diseases. *J Atheroscler Thromb* 2019;26(04):303–314
- 67 Mital A. Acquired von Willebrand syndrome. *Adv Clin Exp Med* 2016;25(06):1337–1344
- 68 Lucchese G, Kanduc D. The Guillain-Barré peptide signatures: from Zika virus to campylobacter, and beyond. *Virus Adaptation and Treatment* 2017;9:1–11
- 69 Lucchese G, Kanduc D. Minimal immune determinants connect Zika virus, human Cytomegalovirus, and Toxoplasma gondii to microcephaly-related human proteins. *Am J Reprod Immunol* 2017;77(02):e12608
- 70 Kanduc D, Shoenfeld Y. Inter-pathogen peptide sharing and the original antigenic sin: solving a paradox. *Open Immunol J* 2018;8:16–27
- 71 Kanduc D. Anti-SARS-CoV-2 immune response and sudden death: titin as a link. *Adv Stud Biol* 2021;13:37–44
- 72 Francis T, Salk JE, Quilligan JJ. Experience with vaccination against influenza in the spring of 1947: a preliminary report. *Am J Public Health Nations Health* 1947;37(08):1013–1016
- 73 Davenport FM, Hennessy AV, Francis T Jr. Epidemiologic and immunologic significance of age distribution of antibody to antigenic variants of influenza virus. *J Exp Med* 1953;98(06):641–656
- 74 Halstead SB. Which dengue vaccine approach is the most promising, and should we be concerned about enhanced disease after vaccination? There is only one true winner. *Cold Spring Harb Perspect Biol* 2018;10(06):a030700. Doi: 10.1101/cshperspect.a030700
- 75 Natale C, Giannini T, Lucchese A, Kanduc D. Computer-assisted analysis of molecular mimicry between human papillomavirus 16 E7 oncoprotein and human protein sequences. *Immunol Cell Biol* 2000;78(06):580–585



- 76 Kanduc D. Peptide cross-reactivity: the original sin of vaccines. *Front Biosci (Schol Ed)* 2012;4:1393–1401
- 77 Kanduc D. Immunogenicity, immunopathogenicity, and immunotolerance in one graph. *Anticancer Agents Med Chem* 2015;15(10):1264–1268
- 78 Kanduc D. From anti-SARS-CoV-2 immune responses to COVID-19 via molecular mimicry. *Antibodies (Basel)* 2020;9(03):33
- 79 Kanduc D. Immunobiology: on the inexistence of a negative selection process. *Adv Stud Biol* 2020;12:19–28
- 80 Kanduc D. Hydrophobicity and the physico-chemical basis of immunotolerance. *Pathobiology* 2020;87(04):268–276
- 81 Kanduc D. The role of proteomics in defining autoimmunity. *Expert Rev Proteomics* 2021;18(03):177–184